Study reveal single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML patients to reveal resistance mechanisms to the Bcl-2 inhibitor venetoclax and ...
TipRanks on MSN11h
Syncona’s Autolus Gains FDA Approval for Leukemia Therapy
Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...
Medscape2d
FDA Approved Obe-cel, a Novel CD19 CAR T Product for ALL
Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.
Managed Healthcare Executive2d
Updated: FDA Approves Aucatzyl for Adults with Aggressive Leukemia
Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...
precisionmedicineonline2d
FDA Approves Autolus' CAR T-Cell Therapy Aucatzyl for B-Cell Acute Lymphoblastic Leukemia
The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.
Targeted Oncology2d
FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL
The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.